Nozomi Niitsu

Summary

Affiliation: Saitama Medical School
Country: Japan

Publications

  1. ncbi request reprint Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
    Nozomi Niitsu
    Department of Hematology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama 350 0495, Japan
    Leuk Res 29:1361-4. 2005
  2. ncbi request reprint Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma
    N Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Ann Oncol 18:1203-8. 2007
  3. ncbi request reprint Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Leuk Res 31:1191-7. 2007
  4. doi request reprint A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma
    N Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Ann Oncol 19:1941-6. 2008
  5. ncbi request reprint Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Ann Hematol 85:374-80. 2006
  6. doi request reprint Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Leuk Res 32:1837-41. 2008
  7. ncbi request reprint Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Saitama 350 0495, Japan
    Cancer Sci 97:933-7. 2006
  8. ncbi request reprint t(8;14)(q24;q32) in two patients with CD10-negative primary thyroid diffuse large B-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Res 31:707-11. 2007
  9. ncbi request reprint Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Department of Internal Medicine, Hematology Division, Saitama Medical University, Iruma gun, Saitama, Japan
    Hematol Oncol 24:220-6. 2006
  10. ncbi request reprint Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Cancer Sci 98:109-12. 2007

Detail Information

Publications55

  1. ncbi request reprint Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
    Nozomi Niitsu
    Department of Hematology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama 350 0495, Japan
    Leuk Res 29:1361-4. 2005
    ..The effectiveness of the chemotherapy could confirm our diagnosis, although MALT-type lymphoma with plasmacytic differentiation cannot be completely ruled out...
  2. ncbi request reprint Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma
    N Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Ann Oncol 18:1203-8. 2007
    ..We studied the clinicopathological characteristics and prognoses of localized stage thyroid diffuse large B-cell lymphoma (DLBCL)...
  3. ncbi request reprint Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Leuk Res 31:1191-7. 2007
    ..PFS rate was significantly higher in the DLBCL patients with 3q27 translocation than in those with 18q21 translocation. These findings suggest that the presence of 3q27 translocation is a significant prognostic factor in DLBCL...
  4. doi request reprint A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma
    N Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Ann Oncol 19:1941-6. 2008
    ..We carried out immunohistochemistry to examine the expression of nm23-H1 in Hodgkin and Reed-Sternberg cells in patients with classical Hodgkin's lymphoma (CHL)...
  5. ncbi request reprint Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Ann Hematol 85:374-80. 2006
    ..The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy...
  6. doi request reprint Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Leuk Res 32:1837-41. 2008
    ..The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state...
  7. ncbi request reprint Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Saitama 350 0495, Japan
    Cancer Sci 97:933-7. 2006
    ..The R-CMD regimen was safe in elderly patients with DLBCL. No new signs of cardiotoxicity were observed with this regimen. It was also effective in patients with relapsed or refractory DLBCL who had previously used DXR...
  8. ncbi request reprint t(8;14)(q24;q32) in two patients with CD10-negative primary thyroid diffuse large B-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Res 31:707-11. 2007
    ....
  9. ncbi request reprint Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Department of Internal Medicine, Hematology Division, Saitama Medical University, Iruma gun, Saitama, Japan
    Hematol Oncol 24:220-6. 2006
    ..We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission...
  10. ncbi request reprint Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Cancer Sci 98:109-12. 2007
    ..In addition, it was effective in patients who had previously been treated with doxorubicin and good treatment results were obtained in elderly patients with relapsed PTCL...
  11. doi request reprint Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma
    Nozomi Nitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Cancer Sci 100:233-7. 2009
    ..It will be necessary to study whether more aggressive chemotherapy or rituximab combination chemotherapy is effective in 8q24 translocation cases...
  12. doi request reprint Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
    N Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Leukemia 23:777-83. 2009
    ..In this study, only a few patients received rituximab, and its usefulness could not be assessed. Future studies with larger numbers of patients are required...
  13. doi request reprint Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers
    Nozomi Niitsu
    Department of Haematology, International Medical Centre, Saitama Medical University, Saitama Adult Lymphoma Treatment Study Group, Nagoya, Japan
    Br J Haematol 153:582-8. 2011
    ..Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL...
  14. doi request reprint Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy
    Nozomi Niitsu
    Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    J Clin Oncol 28:5097-100. 2010
    ..In this prospective study, the frequency of and risk factors for HBV reactivation in patients who were receiving rituximab chemotherapy were examined...
  15. doi request reprint A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama, 350 1298, Japan
    Ann Hematol 90:185-92. 2011
    ..These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL...
  16. doi request reprint Current treatment strategy of diffuse large B-cell lymphomas
    Nozomi Niitsu
    Department of Hematology, Saitama Medical University, Hidaka, Saitama, Japan
    Int J Hematol 92:231-7. 2010
    ..For young, high-risk DLBCL patients, treatment that incorporates rituximab and hematopoietic stem cell transplantation has been administered in clinical studies...
  17. doi request reprint Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Hematol Oncol 26:152-8. 2008
    ..PTCL-U is a heterogeneous disease with regard to histological type and pathological state. Because PTCL-U is generally not responsive to CHOP therapy, new treatment strategies need to be developed...
  18. doi request reprint Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Hematol Oncol 28:68-74. 2010
    ..Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL...
  19. doi request reprint Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma
    N Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama, Japan
    Ann Oncol 21:2069-74. 2010
    ..CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared...
  20. doi request reprint Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Cancer Sci 101:1309-13. 2010
    ..Germinal center B-cell type and EBER-positive patients tended to show spontaneous remission. The utility of rituximab should be examined in future studies...
  21. doi request reprint Renal intravascular large B-cell lymphoma with early diagnosis by renal biopsy: a case report and review of the literature
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama, 350 1298 Japan
    Leuk Res 33:728-30. 2009
    ..We could perform early diagnosis by renal biopsy and were able to achieve long-term remission by rituximab combination chemotherapy...
  22. ncbi request reprint Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma
    Nozomi Niitsu
    Hematology Division, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Lymphoma 47:1908-14. 2006
    ..However, a long-term risk of the BEACOPP regimen is the development of secondary leukemia or myelodysplastic syndrome. Therefore, long-term follow-up of these patients, including monitoring for toxicities, is necessary...
  23. doi request reprint Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, 1 15 1 Kitasato, Minami Ku, Sagamihara, 252 0374, Japan
    Ann Hematol 91:997-1005. 2012
    ..3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal. Our findings indicate that the CD20 level (FCM) at onset is an independent predictor of the prognosis of patients with DLBCL...
  24. ncbi request reprint t(6;14)(q15;q32) in a patient with CD5+CD10+ diffuse large B-cell lymphoma
    Miyuki Hayama
    Department of Hematology, Kitasato University, Sagamihara shi, Kanagawa, Japan
    Int J Hematol 86:147-9. 2007
    ..Regarding CD5+CD10+ diffuse large B-cell lymphoma with a non-random chromosomal translocation of t(6;14)(q15;q32), studies on the mechanism of lymphomagenesis are needed...
  25. ncbi request reprint [Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma]
    Kumiko Yoshitake
    Department of Hematology, International Medical Center, Saitama Medical University
    Rinsho Ketsueki 51:196-200. 2010
    ....
  26. doi request reprint Incidence and clinical significance of aberrant T-cell marker expression on diffuse large B-cell lymphoma cells
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan
    Acta Haematol 130:230-7. 2013
    ..We conducted a retrospective study to establish its incidence and to determine its relationship with clinical features of patients with diffuse large B-cell lymphoma (DLBCL)...
  27. doi request reprint Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review
    Yuhko Suzuki
    Department of Hematology, School of Medicine, Kitasato University, Sagamihara, Japan
    Acta Haematol 121:21-6. 2009
    ..We report DLBCL after immunosuppressive therapy for AA. Although this is a rare complication, it should be considered before beginning immunosuppressive therapy...
  28. ncbi request reprint Alveolar rhabdomyosarcoma mimicking nasal lymphoma at the initial presentation
    Tatsuya Ihara
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    J Clin Exp Hematop 48:61-4. 2008
    ..We conclude that rhabdomyosarcoma should be included in the differential diagnoses of CD56(+) small round cell tumor, and immunohistochemical and cytogenetic studies should be performed...
  29. doi request reprint The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma
    Yuichi Nakamura
    Department of Hematology, Saitama Medical University, 38 Morohongo, Moroyama machi, Iruma gun, Saitama 350 0495, Japan
    Cancer Genet Cytogenet 182:144-9. 2008
    ..The GAS5 gene on chromosome 1q25 is the second BCL6 partner, to the SNHG5 on 6q15, which is classified as a non-protein-coding multiple snoRNA host and 5'-TOP class gene...
  30. doi request reprint Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature
    Yoko Shimizu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama 350 1298, Japan
    Leuk Res 34:263-6. 2010
    ..C-ALCL is generally a disorder that progresses slowly and has a good prognosis. Manifestation of a giant ulcer and hemophagocytic syndrome, such as in the present case, is rare...
  31. ncbi request reprint Successful radiotherapy in a patient with primary rectal mucosa-associated lymphoid tissue lymphoma without the API2-MALT1 fusion gene: a case report and review of the literature
    Taisuke Kobayashi
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama 350 1298, Japan
    Leuk Res 32:173-5. 2008
    ..The patient was negative for API2-MALT1 gene, and radiotherapy was performed and CR was achieved. With the accumulation of cases, establishment of a treatment strategy for primary rectal MALT lymphoma is expected in the future...
  32. pmc Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type
    Naoko Asano
    Department of Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan
    Haematologica 96:1636-43. 2011
    ..However, the clinical characteristics of cytotoxic molecule-positive classical Hodgkin's lymphoma remain controversial...
  33. ncbi request reprint [The stratification treatment that was based on a prognostic factor of malignant lymphoma]
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University
    Nihon Rinsho 65:534-9. 2007
  34. ncbi request reprint CD3- and CD4-positive plasmablastic lymphoma: a literature review of Japanese plasmablastic lymphoma cases
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan
    Intern Med 49:1801-5. 2010
    ..He was diagnosed as a plasmablastic lymphoma; radiation therapy (RT) was started, but the response to the RT was only a partial response. To our knowledge, this is the first report of a patient with PBL expressing CD3 and CD4...
  35. doi request reprint Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis
    Daisuke Ennishi
    Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Blood 116:5119-25. 2010
    ..HCV-RNA levels significantly increased during immunochemotherapy (P = .006). These results suggest that careful monitoring of hepatic function and viral load is indicated during immunochemotherapy for HCV-positive patients...
  36. doi request reprint Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients
    Kazuyuki Shimada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer Sci 101:1480-6. 2010
    ..Central nervous system recurrence is a serious complication in IVLBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era...
  37. doi request reprint Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specified
    Nozomi Niitsu
    Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan
    Clin Cancer Res 17:2893-9. 2011
    ..We examined whether nm23-H1 is a prognostic factor of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)...
  38. doi request reprint Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells
    Yuki Hagiwara
    Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina machi, Kitaadachi gun, Saitama, Japan
    Int J Hematol 92:136-43. 2010
    ..These results indicate that EA is a potent apoptosis inducer and also effectively potentiates ATRA-induced myeloid differentiation of HL-60 cells...
  39. ncbi request reprint Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Br J Haematol 123:621-30. 2003
    ..The nm23-H1 protein can be an important prognostic factor in the lymphomas studied here. New treatments that target nm23 overexpression could be developed as a result of nm23-HI production by lymphoma cells...
  40. ncbi request reprint Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Eur J Haematol 68:91-100. 2002
    ..Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma...
  41. ncbi request reprint Ovarian follicular lymphoma: a case report and review of the literature
    Nozomi Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa, 228 8555, Japan
    Ann Hematol 81:654-8. 2002
    ..Since the prognosis for primary ovarian lymphoma is relatively favorable in many cases, it is important to establish therapeutic methods for the cure of this disease using chemotherapy and radiotherapy without radical surgery...
  42. ncbi request reprint High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine, Internal Medicin IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:241-8. 2002
    ..the results of a multivariate analysis showed that the five IPI prognostic factors and the sCD44 level were independent prognostic factors, thus suggesting that sCD44 levels could be a useful prognostic marker for aggressive lymphoma..
  43. ncbi request reprint Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma
    Tadashi Yoshino
    Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Br J Haematol 118:482-7. 2002
    ..In conclusion, the present findings established that CLA is an independent and important prognostic factor in patients with NK-cell lymphomas...
  44. ncbi request reprint [Clinical significance of biological prognostic factors in non-Hodgkin lymphoma: analysis of serum and cell surface nm 23-H1 protein]
    Nozomi Niitsu
    Rinsho Ketsueki 44:211-8. 2003
  45. doi request reprint Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan
    Kazuyuki Shimada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550 Japan
    J Clin Oncol 26:3189-95. 2008
    ..To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL)...
  46. ncbi request reprint Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Clin Cancer Res 11:697-702. 2005
    ..Doxorubicin is often given during the initial treatment. The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy...
  47. ncbi request reprint Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature
    Nozomi Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Eur J Haematol 73:367-71. 2004
    ..Pregnancy-associated lymphoma is resistant to standard chemotherapy and is associated with poor prognosis. Therefore, it is important to accumulate clinicopathologic data of such cases for the development of a treatment modality...
  48. ncbi request reprint Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Clin Cancer Res 10:4077-82. 2004
    ..Granulocyte colony-stimulating factor (G-CSF) enhances the cytotoxicity of neutrophils through ADCC, and it can be speculated that a combination of rituximab and G-CSF may augment the treatment efficacy of rituximab...
  49. ncbi request reprint Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Clin Cancer Res 10:2482-90. 2004
    ..Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin's lymphoma...
  50. ncbi request reprint [Successful radiotherapy for the thoracic cord infiltration of adult T-cell leukemia/lymphoma]
    Nobu Akiyama
    Department of Internal Medicine IV, Section of Hematology, School of Medicine, Kitasato University
    Rinsho Ketsueki 44:1095-100. 2003
    ..Administration of intrathecal methotrexate and prednisolone, systemic dexamethasone and local irradiation of 30 Gy improved the paralysis and the abnormal MRCT findings. Rehabilitation restored the patient's ability to walk...
  51. ncbi request reprint The t(1;3)(p34;q27) translocation: a nonrandom BCL6 rearrangement in diffuse large B cell lymphoma
    Nozomi Niitsu
    Ann Hematol 87:151-3. 2008
  52. ncbi request reprint Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:745-55. 2002
    ....
  53. ncbi request reprint Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid
    Kimiko Iijima
    First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
    Leuk Lymphoma 45:1017-24. 2004
    ..Pretreatment with TSA before exposure to ATRA displayed increased effect. Based on these findings, combined treatment with ATRA and TSA may be clinically useful in therapy for acute leukemia displaying MLL-AF9 fusion gene...
  54. ncbi request reprint Lymphoid neoplasms associated with mosquito bites
    Naoki Wakimoto
    Intern Med 44:1118-9. 2005
  55. ncbi request reprint Prognostic factors in diffuse large B-cell lymphoma
    Nozomi Niitsu
    Intern Med 45:227-8. 2006